ExeVir Bio
Clinical-stage biotechnology company developing nanobody-based therapeutics for infectious diseases
ExeVir Bio has raised €25M across 1 funding round from 1 investor, most recently a Debt round in Jan 2023. Based in Belgium; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€25M
€25,000,000
Funding rounds
1
Investors
1
distinct backers
Active since
2023-01
latest 2023-01
Funding by year
EUR raised per yearExeVir Bio — funding by year — interactive chart.
Data table
| ExeVir Bio — funding by year | |
|---|---|
| 2023 | €25M |
Signals
High confidenceRaise-next likelihood8
base rate 45% for Debt
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-01-09 | Debt | €25M | European Investment Bank | View deal → |
Investors
1Related news
- Belgium’s ExeVir raises €25M from EIB to develop novel COVID-19 therapeuticsiliconcanals.com · 2023-01
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Imec€2.5BBelgium · Deeptech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Kpler€1.0BBelgium · Software
Global coverage: FundingData